Skip to main content
SpringerLink
Log in

Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients

  • Original Papers
  • Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Breast cancer tissue was examined for overexpression of HER-2/neu and p53 oncogene proteins. Samples from 105 breast cancer patients were investigated by Western-blot analysis and their relationship to other established markers and clinical outcome was examined. In 21.0% of the cases HER-2/neu was overexpressed, and in 46.7% the p53 protein level was increased. Expression of these two oncogene products was closely correlated. Overexpression of both oncogenes was associated with larger tumour size and negative hormone receptor. The percentage of HER-2/neu and p53 overexpression was higher in node-positive patients, although statistical evaluation was not significant. While overexpression of HER-2/neu as well as p53 in node-positive patients was associated insignificantly with shorter disease-free survival, a significant difference could be documented when the disease-free survival of patients with overexpression of both oncogene proteins was compared to that of patients with no overexpression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjanen K (1993) Comparison of classic and quantitative prognostic factors in hormone receptor-positive and hormone receptor-negative female breast cancer. Am J Surg 165:307–311

    PubMed  Google Scholar 

  • Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200–206

    PubMed  Google Scholar 

  • Bargmann CI, Hung MC, Weinberg RA (1986) Multiple independent activations of theneu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649–657

    PubMed  Google Scholar 

  • Bishop JM (1987) The molecular genetics of cancer (review). Science 235:305–311

    PubMed  Google Scholar 

  • Chang K, Ding I, Kern FG, Willingham MC (1991) Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors. J Histochem Cytochem 39:1281–1287

    PubMed  Google Scholar 

  • Clark GM (1992) Integrating prognostic factors. Breast Cancer Res Treat 22:187–191

    PubMed  Google Scholar 

  • Clark GM, McGuire WL (1991) Follow-up study of HER-2/neu amplification in primary breast cancer (review). Cancer Res 51:944–948

    PubMed  Google Scholar 

  • Contesso G, Jotti GS, Bonadonna G (1989) Tumor grade as a prognostic factor in primary breast cancer (review). Eur J Cancer Clin Oncol 25:403–409

    PubMed  Google Scholar 

  • Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139

    PubMed  Google Scholar 

  • Crawford LV, Pim DC, Lamb P (1984) The cellular protein p53 in human tumors. Mol Biol Med 2:261–272

    PubMed  Google Scholar 

  • Davidoff AM, Herndon JE, Glover NS, Kerns BJ, Pence JC, Iglehart JD, Marks JR (1991) Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110:259–264

    PubMed  Google Scholar 

  • Eliyahu D, Michalovitz D, Oren M (1985) Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 316:158–160

    PubMed  Google Scholar 

  • Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, McGuire WL (1993) Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 26:225–235

    PubMed  Google Scholar 

  • Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083–1093

    PubMed  Google Scholar 

  • Gannon JV, Greaves R, Iggo R, Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595–1602

    PubMed  Google Scholar 

  • Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, et al [International (Ludwig) Breast Cancer Study Group] (1992) Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049–1056

    PubMed  Google Scholar 

  • Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene (review). N Engl J Med 329:1318–1327

    PubMed  Google Scholar 

  • Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations is human cancers (review). Science 253:49–53

    PubMed  Google Scholar 

  • Ji H, Lipponen P, Aaltomaa S, Syrjanen S, Syrjanen K (1993) c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res 13:1147–1152

    PubMed  Google Scholar 

  • Kerns BJ, Jordan PA, Huper G, Marks JR, Iglehart JD, Layfied LJ (1993) Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Mod Pathol 6:673–678

    PubMed  Google Scholar 

  • King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976

    PubMed  Google Scholar 

  • Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261–263

    PubMed  Google Scholar 

  • Linzer DI, Levine AJ (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43–52

    PubMed  Google Scholar 

  • Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170

    PubMed  Google Scholar 

  • Molina R, Ciocca DR, Tandon AK, Allred DC, Clark GM, Chamness GC, Gullick WJ, McGuire WL (1992) Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. Anticancer Res 12:1965–1971

    PubMed  Google Scholar 

  • Parada LF, Land H, Weinberg RA, Wolf D, Rotter V (1984) Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312:649–651

    PubMed  Google Scholar 

  • Pinhasi-Kimhi O, Michalovitz D, Ben-Zeev A, Oren M (1986) Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature 320:182–184

    PubMed  Google Scholar 

  • Semba K, Kamata N, Toyoshima K, Yamamoto T (1985) A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497–6501

    PubMed  Google Scholar 

  • Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U (1993) p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965–970

    PubMed  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    PubMed  Google Scholar 

  • Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid [published erratum appears in Anal Biochem (1987) 163:279]. Anal Biochem 150:76–85

    PubMed  Google Scholar 

  • Tainsky MA, Bischoff F, Strong LC (1992) A dual role for p53 in the progression of human cells toward cancer. Proc Am Assoc Cancer Res 33:2274

    Google Scholar 

  • Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL (1989) HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120–1128

    PubMed  Google Scholar 

  • Thor AD, Moore DH,II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, et al (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845–855

    PubMed  Google Scholar 

  • Toikkanen S, Helin H, Isola J, Joensuu H (1992) Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10:1044–1048

    PubMed  Google Scholar 

  • Venter DJ, Tuzi NL, Kumar S, Gullick WJ (1987) Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet II:69–72

    Google Scholar 

  • Vijver MJ van de, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R (1988) Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239–1245

    PubMed  Google Scholar 

  • Vogelstein BA (1990) A deadly inheritance. Nature 348:681–682

    PubMed  Google Scholar 

  • Zeillinger R, Kury F, Czerwenka K, Kubista E, Sliutz G, Knogler W, Huber J, Zielinski C, Reiner G, Jakesz R, et al (1989) HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4:109–114

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria

    C. Wiltschke & A. Steininger

  2. Institute of Tumor Biology and Cancer Research, University of Vienna, Austria

    I. Kindas-Muegge

  3. Department of Pathology, University of Vienna, Austria

    A. Reiner

  4. Ist Surgical Clinic, University of Vienna, Austria

    G. Reiner

  5. Allgemein Oeffentliches Krankenhaus, Waidhofen/Thaya, Austria

    P. N. Preis

Authors
  1. C. Wiltschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Kindas-Muegge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Steininger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Reiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Reiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. N. Preis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiltschke, C., Kindas-Muegge, I., Steininger, A. et al. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J Cancer Res Clin Oncol 120, 737–742 (1994). https://doi.org/10.1007/BF01194273

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01194273

Key words

Search

Navigation